DALLAS, Aug. 12, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Jazz Pharmaceuticals Inc. (Nasdaq:JAZZ). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/lp/JAZZ
Jazz Pharmaceuticals Inc. (JAZZ) is a specialty pharmaceutical company focused on developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) extended-release capsules and JZP-6 (sodium oxybate). The other product candidates in clinical development are JZP-8 (intranasal clonazepam), being developed for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens, JZP-4 (sodium and calcium channel antagonist), being developed for the treatment of epilepsy and bipolar disorder, and JZP-7 (ropinirole gel), being developed for the treatment of restless legs syndrome.
Message Board Search for JAZZ: http://www.boardcentral.com/boards/JAZZ
In the report, the analyst notes:
"JAZZ recently announced financial results for the second quarter ended June 30, 2010, and updated financial guidance for 2010. The Company's updated financial guidance reflects higher expected sales of XYREM® (sodium oxybate) and the effects of recent financing activities. Total revenues for the quarter ended June 30, 2010, were $40.5 million, compared to $37.3 million for the quarter ended June 30, 2009. Total revenues included net product sales, royalties and contract revenues.
"JAZZ recently announced that it has prepaid the remaining $63.5 million principal amount of its 15% senior secured notes. The prepayment was made using a combination of borrowings under a new term loan and revolving credit facility with Silicon Valley Bank that closed on June 30, 2010, and cash on hand. The $50 million term loan will amortize in twelve equal quarterly installments of $4.2 million."
To read the entire report visit: www.microstockprofit.com/lp/JAZZ
See what investors are saying about JAZZ at http://www.stockhideout.com
Get breaking news on JAZZ at http://thestockmarketwatch.com/
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.